News Releases

These are news releases that are related to our company, pipeline and investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.

Mar 1, 2017

Summary Toggle aTyr Pharma to Present at Cowen and Company 37th Annual Health Care Conference

SAN DIEGO , March 1, 2017 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced the Company's presentation at the Cowen and Company 37 th Annual
Feb 28, 2017

Summary Toggle aTyr Pharma Receives U.S. FDA Orphan Drug Designation for the Treatment of Limb Girdle Muscular Dystrophy with Resolaris™

SAN DIEGO , Feb. 28, 2017 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced that its product candidate Resolaris™ was granted Orphan Drug
Jan 18, 2017

Summary Toggle FDA Grants Fast Track Designation for aTyr's Resolaris™ to Treat Limb Girdle Muscular Dystrophy 2B and Removes Partial Clinical Hold for Resolaris

- First Reported Fast Track Designation for LGMD2B Treatment - SAN DIEGO , Jan. 18, 2017 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today
Jan 4, 2017

Summary Toggle aTyr Pharma to Present at 35th Annual J.P. Morgan Healthcare Conference

SAN DIEGO , Jan. 4, 2017 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced the Company's participation at the 35 th Annual J.P.
Dec 13, 2016

Summary Toggle aTyr Pharma Reports Promising Signals of Clinical Activity in Multiple Rare Genetically Distinct Myopathies with Resolaris™ in Exploratory Trials

- Improved Muscle Strength Observed in 50% to 78% of Patients in Two Rare Genetically Distinct Myopathies - - Resolaris Continues to Demonstrate a Generally Well Tolerated Safety Profile in All Trials - - Conference Call and Webcast Featuring Guest Speaker Professor John Vissing, MD, at 8:30 a.m.
Dec 9, 2016

Summary Toggle aTyr Pharma to Present at the BMO Prescriptions for Success Healthcare Conference

SAN DIEGO , Dec. 9, 2016 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced that senior management will participate in a fireside chat at the
Nov 21, 2016

Summary Toggle aTyr Pharma Enters into $20 Million Credit Facility

SAN DIEGO , Nov. 21, 2016 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced it has entered into a $20 million credit facility with Silicon Valley
Nov 14, 2016

Summary Toggle aTyr Pharma Announces Third Quarter 2016 Operating Results

- Data Readouts from Three Clinical Trials of Resolaris™ in Rare Myopathies On Track for December 2016 - SAN DIEGO , Nov. 14, 2016 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to
Nov 3, 2016

Summary Toggle aTyr Pharma to Present at Three Upcoming Conferences in November

SAN DIEGO , Nov. 3, 2016 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced its participation in three upcoming conferences.
Oct 24, 2016

Summary Toggle aTyr Pharma Receives FDA Fast Track Designation for Resolaris™ to Treat Facioscapulohumeral Muscular Dystrophy (FSHD)

-- First Reported Fast Track Designation for a FSHD Treatment -- SAN DIEGO , Oct. 24, 2016 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today